Ibrutinib as first line therapy for mantle cell lymphoma: A multicentre, real-world UK study

Ann Tivey,Rohan Shotton,Toby A. Eyre,David Lewis,Louise Stanton, Rebecca Allchin,Harriet Walter,Fiona Miall, Rui Zhao,Anna Santarsieri,Rory McCulloch,Mark Bishton,Amy Beech, Victoria Willimott, Nicole Fowler, Claudia Bedford, Jack Goddard, Sam Protheroe,Angharad Everden,David Tucker

Blood Advances（2023）

引用 0|浏览2

暂无评分

摘要

1.Ibrutinib +/- rituximab was effective and well tolerated as first line MCL therapy. Outcomes were worse in patients with high-risk disease.2.Novel approaches are needed for patients with high-risk MCL and those with progressive disease after first-line ibrutinib

查看译文

关键词

Mantle cell lymphoma,ibrutinib,rituximab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要